Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT05567185
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
- NCT05567185 ↗
- Active, not recruiting
- Janssen Pharmaceutical K.K.
- Focused
We haven't built an HCP commentary report on NCT05567185 (TAR-210 in bladder cancer with FGFR mutations or fusions) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT05567185 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Bluesky threads | 4 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of TAR-210 in Japanese Participants With Bladder Cancer and Selected FGFR Mutations or Fusions
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Urinary Bladder Neoplasms; Receptors, Fibroblast Growth Factor
- Interventions
- Erdafitinib Intravesical Delivery System
- Arms
- Dose Escalation: Erdafinitib Intravesical Delivery System · Experimental
- Enrollment
- 5
- Primary outcomes
- Number of Participants with Dose-limiting Toxicity (DLT)
- Sponsor
- Janssen Pharmaceutical K.K.
- Start
- Mar 3, 2023
- Primary completion
- Mar 11, 2025
- Results posted
- No
- Registry record
- NCT05567185 · updated Aug 28, 2026